In conclusion, our results indicate that the <i>ERCC1</i> rs3212986 and the <i>ERCC2/XPD</i> rs1799793 could be used as surrogate markers for a better stratification of EC patients with advanced resectable tumor.
In the present meta-analysis, we demonstrated that the ERCC1 rs3212986 polymorphism was significantly correlated with the response rate of esophageal cancer patients to neoadjuvant therapy (OR = .49, 95% CI = 0.31-0.76, heterogeneity P = 0.480).
Our study indicates the ERCC1 rs3212986 as a predictive marker in the cisplatin/5-FU-based neoadjuvant setting, and also suggests its use as a marker to select the appropriate therapeutic approach in esophageal cancer patients.